Therabene

American biotechnology company From Wikipedia, the free encyclopedia

Therabene is an American biotechnology company founded in 2020 that develops PROTAC drugs targeting proteins such as CDK9 and MYC for cancer treatment.[1][2]

Company typePrivate
HeadquartersNorwood, Massachusetts, U.S.
Quick facts Company type, Industry ...
Therabene
Company typePrivate
IndustryBiotechnology
FoundedMansfield, Massachusetts, U.S.
HeadquartersNorwood, Massachusetts, U.S.
Key people
Mario DiPaola (CEO)
Zoser Mohamed (President)
Oscar Kashala (CMO)
Websitewww.therabene.com
Close

History

Therabene was founded in 2020 by Mario DiPaola and initially operated from the Mansfield Bio-Incubator. The company later relocated its headquarters to Norwood, Massachusetts.[3][4][5]

In 2024, it reported preclinical results for two molecules showing tumor reduction in a triple-negative breast cancer model. In 2025, Oscar L. Kashala was appointed chief medical officer.[6][7][8]

Products

Therabene develops inhibitors and degraders targeting CDK9 and MYC for cancer treatment. Its pipeline includes TB-003, TB-008, TB-010, and TB-M002, which are in preclinical development.[9][10][11]

References

Related Articles

Wikiwand AI